All In Biotech

Drug Trial Radar · NCT02018861

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

88

Actual

Start

Sep 22, 2016

Primary completion

Apr 12, 2021

Study completion Apr 12, 2021

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Dec 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1 inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.

Conditions

  • B-Cell Malignancies

Interventions

  • ParsaclisibDrug

  • ItacitinibDrug

  • RituximabDrug

  • IfosfamideDrug

  • CarboplatinDrug

  • EtoposideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 53 months (4.4 years)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham Comprehensive Cancer Center

    Birmingham, Alabama

  • University of Michigan Cancer Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Nyu Langone Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • University Hospitals Case Medical Center

    Cleveland, Ohio

  • Greenville Health System Cancer Institute

    Greenville, South Carolina

  • Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.